Artiva Biotherapeutics, Inc. (ARTV)
(Delayed Data from NSDQ)
$15.83 USD
+0.43 (2.79%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $15.81 -0.02 (-0.13%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ARTV 15.83 +0.43(2.79%)
Will ARTV be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ARTV based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ARTV
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
Buy Rating Affirmed for Artiva Biotherapeutics on Promising AlloNK Developments and Trial Optimism
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Artiva Biotherapeutics GAAP EPS of -$22.00
Wedbush bullish on Artiva Biotherapeutics, initiates with an Outperform